B
Bruno Royer
Researcher at University of Paris
Publications - 139
Citations - 5680
Bruno Royer is an academic researcher from University of Paris. The author has contributed to research in topics: Multiple myeloma & Transplantation. The author has an hindex of 38, co-authored 121 publications receiving 4811 citations. Previous affiliations of Bruno Royer include French Institute of Health and Medical Research.
Papers
More filters
Journal ArticleDOI
High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.
Arnaud Jaccard,Philippe Moreau,Véronique Leblond,Xavier Leleu,Lofti Benboubker,Olivier Hermine,Christian Recher,Bouchra Asli,Bruno Lioure,Bruno Royer,Fabrice Jardin,Franck Bridoux,Bernard Grosbois,Jérôme Jaubert,Jean-Charles Piette,Pierre Ronco,Fabrice Quet,Michel Cogné,Jean-Paul Fermand +18 more
TL;DR: The outcome of treatment of AL amyloidosis with high-doseMelphalan plus autologous stem-cell rescue was not superior to the outcome with standard-dose melphalanplus dexamethasone.
Journal ArticleDOI
High-Dose Therapy and Autologous Blood Stem-Cell Transplantation Compared With Conventional Treatment in Myeloma Patients Aged 55 to 65 Years: Long-Term Results of a Randomized Control Trial From the Group Myelome-Autogreffe
Jean-Paul Fermand,Sandrine Katsahian,Marine Divine,Véronique Leblond,François Dreyfus,Margaret Macro,Bertrand Arnulf,Bruno Royer,Xavier Mariette,Edouard Pertuiset,Coralie Belanger,Maud Janvier,Sylvie Chevret,Jean Claude Brouet,Philippe Ravaud +14 more
TL;DR: This randomized trial confirmed a benefit ofHDT in terms of EFS and TwiSTT but did not provide evidence for superiority of HDT over CCT in OS of patients aged 55 to 65 years with symptomatic newly diagnosed MM.
Journal ArticleDOI
Lymphomas in Patients With Sjögren's Syndrome Are Marginal Zone B-Cell Neoplasms, Arise in Diverse Extranodal and Nodal Sites, and Are Not Associated With Viruses
Bruno Royer,Dominique Cazals-Hatem,Jean Sibilia,Félix Agbalika,Jean-Michel Cayuela,Thierry Soussi,Frédéric Maloisel,Jean-Pierre Clauvel,Jean-Claude Brouet,Xavier Mariette +9 more
TL;DR: L lymphomas occurring in patients with an underlying SS are in most cases MZL, and are not associated with viruses known to be present in other types of lymphomas.
Journal ArticleDOI
Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma
Aurore Perrot,Valérie Lauwers-Cances,Jill Corre,Jill Corre,Nelly Robillard,Cyrille Hulin,Marie-Lorraine Chretien,Thomas Dejoie,Sabrina Maheo,Sabrina Maheo,Anne-Marie Stoppa,Brigitte Pegourie,Lionel Karlin,Laurent Garderet,Bertrand Arnulf,Chantal Doyen,Nathalie Meuleman,Bruno Royer,Jean-Richard Eveillard,Lotfi Benboubker,Mamoun Dib,Olivier Decaux,Arnaud Jaccard,Karim Belhadj,Sabine Brechignac,Brigitte Kolb,Cecile Fohrer,Mohamad Mohty,Margaret Macro,Paul G. Richardson,Victoria Carlton,Martin Moorhead,Thomas D. Willis,Malek Faham,Kenneth C. Anderson,Jean-Luc Harousseau,Xavier Leleu,Thierry Facon,Philippe Moreau,Michel Attal,Hervé Avet-Loiseau,Hervé Avet-Loiseau,Nikhil C. Munshi +42 more
TL;DR: The findings confirm the value of MRD status, as determined by NGS, as a prognostic biomarker in multiple myeloma, and suggest that this approach could be used to adapt treatment strategies in future clinical trials.
Journal ArticleDOI
VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial.
Philippe Moreau,Cyrille Hulin,Margaret Macro,Denis Caillot,Carine Chaleteix,Murielle Roussel,Laurent Garderet,Bruno Royer,Sabine Brechignac,Mourad Tiab,Mathieu Puyade,Martine Escoffre,Anne-Marie Stoppa,Thierry Facon,Brigitte Pegourie,Driss Chaoui,Arnaud Jaccard,Borhane Slama,Gerald Marit,Karim Laribi,Pascal Godmer,Odile Luycx,Jean-Claude Eisenmann,Olivier Allangba,Mamoun Dib,Carla Araujo,Jean Fontan,Karim Belhadj,Marc Wetterwald,Véronique Dorvaux,Jean-Paul Fermand,Philippe Rodon,Brigitte Kolb,Sylvie Glaisner,Jean-Valère Malfuson,Pascal Lenain,Laetitia Biron,Lucie Planche,Hélène Caillon,Hervé Avet-Loiseau,Thomas Dejoie,Michel Attal +41 more
TL;DR: The data support the preferential use of VTD rather than VCD in preparation for ASCT, and the rate of peripheral neuropathy was significantly higher in the VTD arm than the VCD arm.